Ethical issues in stem cell research and therapy

Stem Cell Research and Therapy

Volumn 5, Issue 4, 2014, Pages

  King, Nancy M P ^a   Perrin, Jacob ^b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b WAKE FOREST UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOSE TISSUE; AMNION FLUID; BIOETHICS; BIOTECHNOLOGY; CLINICAL TRIAL (TOPIC); EMBRYONIC STEM CELL; HUMAN; MESENCHYMAL STROMA CELL; MULTIPOTENT STEM CELL; NONHUMAN; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REGENERATIVE MEDICINE; REVIEW; SOCIAL JUSTICE; STEM CELL RESEARCH; STEM CELL TRANSPLANTATION; THERAPEUTIC MISCONCEPTION; TRANSLATIONAL RESEARCH; UMBILICAL CORD BLOOD; URINE; BIOLOGICAL THERAPY; CELL CULTURE TECHNIQUE; ETHICS;

CELL CULTURE TECHNIQUES; CELL- AND TISSUE-BASED THERAPY; CLINICAL TRIALS AS TOPIC; EMBRYONIC STEM CELLS; HUMANS; STEM CELL RESEARCH; STEM CELL TRANSPLANTATION;

EID: 84904017119     PISSN: None     EISSN: 17576512     Source Type: Journal    
DOI: 10.1186/scrt474     Document Type: Review

References (53)

1. Resolving ethical issues in stem cell clinical trials: the example of Parkinson disease. B Lo, L Parham, J Law Med Ethics 2010 38 257 266 10.1111/j.1748-720X.2010.00486.x 20579249
2. The inherent ethical challenge of first-in-human pluripotent stem cell trials. MG Habets, JJ van Delden, AL Bredenoord, Regen Med 2014 9 1 3 10.2217/rme.13.83 24350999
3. Stem cell trials for cardiovascular medicine: ethical rationale. SL Niemansburg, M Teraa, H Hesam, JJ van Delden, MC Verhaar, AL Bredenoord, Tiss Eng Part A 2013 [Epub ahead of print]
4. R Levine, Ethics and Regulation of Clinical Research New York: Yale University Press 1988
5. Special Report: Animal research ethics: evolving views and practices. S Gilbert, GE Kaebnick, TH Murray, Hastings Center Rep 2012 42 1 S39
6. Bench to bedside: mapping the moral terrain of clinical research. S Joffe, FG Miller, Hastings Center Rep 2008 38 30 42
7. US Food and Drug Administration international collaborations for cellular therapy product regulation. JA Arcidiacono, JW Blair, KA Benton, Stem Cell Res Ther 2012 3 38 42 10.1186/scrt129 23021082
8. The stem cell research environment: a patchwork of patchworks. T Caulfield, A Zarzeczny, J McCormick, T Bubela, C Critchley, E Einsiedel, J Galipeau, S Harmon, M Huynh, I Hyun, J Illes, R Isasi, Y Joly, G Laurie, G Lomax, H Longstaff, M McDonald, C Murdoch, U Ogbogu, J Owen-Smith, S Pattinson, S Premji, B von Tigerstrom, DE Winickoff, Stem Cell Rev 2009 5 82 88 10.1007/s12015-009-9071-3 19521798
9. Assessing ESCROs: yesterday and tomorrow. H Greely, Am J Bioeth 2013 13 44 52 24256538
10. Stem cell policy exceptionalism: proceed with caution. GP Lomax, SR Peckman, Stem Cell Rev Rep 2012 8 299 304 10.1007/s12015-011-9305-z
11. New ISSCR guidelines underscore major principles for responsible translational stem cell research. I Hyun, O Lindvall, L Ahrlund-Richter, E Cattaneo, M Cavazzana-Calvo, G Cossu, M De Luca, IJ Fox, C Gerstle, RA Goldstein, G Hermeren, KA High, HO Kim, HP Lee, E Levy-Lahad, L Li, B Lo, DR Marshak, A McNab, M Munsie, H Nakauchi, M Rao, HM Rooke, CS Valles, A Srivastava, J Sugarman, PL Taylor, A Veiga, AL Wong, L Zoloth, GQ Daley, Cell Stem Cell 2008 3 607 609 10.1016/j.stem.2008.11.009 19041777
12. Guidelines for the clinical translation of stem cells. International Society for Stem Cell Research, [ http://www.isscr.org/docs/guidelines/ isscrglclinicaltrans.pdf ]
13. Stem cell research and economic promises. T Caulfield, J Law Med Ethics 2010 38 303 313 10.1111/j.1748-720X.2010.00490.x 20579253
14. The evolution of policy issues in stem cell research: an international survey. T Caulfield, C Rachul, A Zarzeczny, Stem Cell Rev Rep 2012 8 1037 1042 10.1007/s12015-012-9404-5
15. What makes clinical research ethical? EJ Emanuel, D Wendler, C Grady, JAMA 2000 283 2701 2711 10.1001/jama.283.20.2701 10819955 (Pubitemid 30337334)
16. Ethical and policy issues in the clinical translation of stem cells: report of a focus session at the ISSCR annual meeting. K Kato, J Kimmelman, J Robert, D Sipp, J Sugarman, Cell Stem Cell 2012 11 765 767 10.1016/j.stem.2012. 11.004 23217422
17. Beyond access vs. protection in trials of innovative therapies. AJ London, J Kimmelman, ME Emborg, Science 2010 328 829 830 10.1126/science.1189369 20466907
18. En route to ethical recommendations for gene transfer clinical trials. NM King, O Cohen-Haguenauer, Mol Ther 2008 16 432 438 10.1038/mt.2008.13 18297094 (Pubitemid 351314980)
19. First-in-human trial participants: not a vulnerable population, but vulnerable nonetheless. R Dresser, J Law Med Ethics 2009 37 38 50 19754651
20. Stem cell research as innovation: expanding the ethical and policy conversation. R Dresser, J Law Med Ethics 2010 38 332 341 10.1111/j.1748-720X. 2010.00492.x 20579255
21. Alive and well: the research imperative. R Dresser, J Law Med Ethics 2012 40 915 921 23289694
22. The ubiquity and utility of the therapeutic misconception. R Dresser, Soc Philos Policy 2002 19 271 294 10.1017/S0265052502192119 12678090
23. Consent forms and the therapeutic misconception: the example of gene transfer research. NM King, GE Henderson, LR Churchill, AM Davis, SC Hull, DK Nelson, PC Parham-Vetter, BB Rothschild, MM Easter, BS Wilfond, IRB 2005 27 1 16425478
24. The bioethics of stem cell research and therapy. I Hyun, J Clin Invest 2010 120 71 75 10.1172/JCI40435 20051638
25. The promise and perils of stem cell therapeutics. GQ Daley, Cell Stem Cell 2012 10 740 749 10.1016/j.stem.2012.05.010 22704514
26. Human stem cell ethics: beyond the embryo. J Sugarman, Cell Stem Cell 2008 2 529 533 10.1016/j.stem.2008.05.005 18522846 (Pubitemid 351729218)
27. Guidance for industry: considerations for the design and conduct of early-phase clinical trials of cellular and gene therapy products (DRAFT). Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research, 2013 [ http://www.fda.gov/downloads/ BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/ CellularandGeneTherapy/UCM359073.pdf ]
28. Direct-to-consumer stem cell marketing and regulatory responses. D Sipp, Stem Cells Translational Med 2013 2 638 640 10.5966/sctm.2013-0040
29. Stem cell therapies could change medicine if they get the chance. I Weissman, Cell Stem Cell 2012 10 663 665 10.1016/j.stem.2012.05.014 22704505
30. New advances in iPS cell research do not obviate the need for human embryonic stem cells. I Hyun, K Hochedlinger, R Jaenish, S Yamanaka, Cell Stem Cell 2007 4 367 368 (Pubitemid 47506540)
31. Pluripotent stem cells: the search for the 'perfect' source. NM King, CN Coughlin, A Atala, Minn J Law Sci Technol 2011 12 715 730
32. Ethical and legal issues arising in research on inducing human germ cells from pluripotent stem cells. T Ishii, RA Pera, HT Greely, Cell Stem Cell 2013 13 145 148 10.1016/j.stem.2013.07.005 23910081
33. CB Cohen, Renewing the Stuff of Life: Stem Cells, Ethics, and Public Policy New York: Oxford University Press 2007
34. Human Embryonic Stem Cell Research Advisory Committee, The National Academies, Final Report and 2010 Amendments to the National Academies' Guidelines for Human Embryonic Stem Cell Research Washington, DC: National Academies Press 2010 24983031
35. Induced pluripotent stem cells: past, present, and future. S Yamanaka, Cell Stem Cell 2012 10 678 684 10.1016/j.stem.2012.05.005 22704507
36. Stem cells: the dark side of induced pluripotency. MF Pera, Nature 2011 471 46 47 10.1038/471046a 21368819
37. Stimulus-triggered fate conversion of somatic cells into pluripotency. H Obokata, T Wakayama, Y Sasai, K Kojima, MP Vacanti, H Niwa, M Yamato, CA Vacanti, Nature 2014 505 641 647 10.1038/nature12968 24476887
38. Acid bath offers easy path to stem cells. D Cyranoski, Nature 2014 505 596 10.1038/505596a 24476866
39. Acid-bath stem-cell study under investigation. D Cyranoski, Nature 2014 [ http://www.nature.com/news/acid-bath-stem-cell-study-under-investigation-1. 14738 ]
40. Stem cell trials: lessons from gene transfer research. J Kimmelman, F Baylis, KG Glass, Hastings Cent Rep 2006 36 23 26 16776020 (Pubitemid 43302111)
41. Allowing innovative stem cell based therapies outside of clinical trials: ethical and policy challenges. I Hyun, J Law Med Ethics 2010 38 277 285 10.1111/j.1748-720X.2010.00488.x 20579251
42. A history lesson for stem cells. JM Wilson, Science 2009 324 727 728 10.1126/science.1174935 19423804
43. Target populations for first-in-human embryonic stem cell research in spinal cords. F Bretzner, F Gilbert, F Baylis, RM Brownstone, Cell Stem Cell 2011 8 468 475 10.1016/j.stem.2011.04.012 21549321
44. Perspectives and future directions of human pluripotent stem cell-based therapies: lessons from Geron's clinical trial for spinal cord injury. D Lukovic, M Stojkovic, V Moreno-Manzano, SS Bhattacharya, S Erceg, Stem Cells Dev 2014 23 1 4 10.1089/scd.2013.0266 23980630
45. Stem cell clinical trials for spinal cord injury: readiness, reluctance, redefinition. J Illes, C Reimer, BK Kwon, Stem Cell Rev 2011 7 997 1005 10.1007/s12015-011-9259-1 21475955
46. The role of body-on-a-chip devices in drug and toxicity studies. MB Esch, TL King, ML Shuler, Ann Rev Biomed Eng 2011 13 55 72 10.1146/annurev-bioeng- 071910-124629
47. Specimen collection for induced pluripotent stem cell research: harmonizing the approach to informed consent. J Lowenthal, S Lipnick, M Rao, SC Hull, Stem Cells Translational Med 2012 1 409 421 10.5966/sctm.2012-0029
48. The DISCUSS project: induced pluripotent stem cell lines from previously collected research biospecimens and informed consent: points to consider. GP Lomax, SC Hull, J Lowenthal, M Rao, R Isasi, Stem Cells Translational Med 2013 2 727 730 10.5966/sctm.2013-0099
49. Return of results in translational iPS cell research: considerations for donor informed consent. GP Lomax, KA Shepard, Stem Cell Res Ther 2013 4 6 7 10.1186/scrt154 23336317
50. The bioethics of iPS cell based drug discovery. I Hyun, Clin Pharmacol Ther 2011 89 646 647 10.1038/clpt.2010.308 21512524
51. Ethical issues in regenerative medicine. NM King, CN Coughlin, M Furth, Wake Forest Intellectual Property Law J 2009 9 216 238
52. Public stem cell banks: considerations of justice in stem cell research and therapy. RR Faden, L Dawson, AS Bateman-House, DM Agnew, H Bok, DW Brock, A Chakravarti, XJ Gao, M Greene, JA Hansen, PA King, SJ O'Brien, DH Sachs, KE Schill, A Siegel, D Solter, SM Suter, CM Verfaillie, LB Walters, JD Gearhart, Hastings Center Rep 2003 33 13 27
53. Science spin: iPSC research in the news. T Caulfield, C Rachul, Clin Pharmacol Ther 2011 89 644 646 10.1038/clpt.2010.309 21512523